Skip to main content

Table 3 Statistical analysis of change from baseline in trough FEV 1 (L) at Week 24 by randomisation strata and ICS dose during run-in (intent-to-treat population)

From: Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

Trough FEV1(Week 24) FF 100 μg FF 200 μg
  (N = 108) (N = 111)
Predicted FEV 1 at baseline
≥ 40% to ≤ 65%
n 45 48
LS mean at baseline 1.561 1.699
LS mean at Week 24 2.368 2.422
LS mean change from baseline (SE) 0.305 (0.074) 0.359 (0.073)
Treatment difference vs. NA 0.055
FF 100 μg (95% CI)   (-0.122, 0.232)
> 65% to ≤ 90%
n 61 61
LS mean at baseline 2.387 2.372
LS mean at Week 24 2.197 2.290
LS mean change from baseline (SE) 0.134 (0.062) 0.227 (0.062)
Treatment difference vs. NA 0.093
FF 100 μg (95% CI)   (-0.061, 0.247)
Run-in ICS use
Mid-dose
n 79 89
LS mean at baseline 2.039 2.085
LS mean at Week 24 2.278 2.340
LS mean change from baseline (SE) 0.222 (0.051) 0.284 (0.047)
Treatment difference vs. NA 0.063
FF 100 μg (95% CI)   (-0.070, 0.195)
High-dose
n 27 19
LS mean at baseline 2.041 1.987
LS mean at Week 24 2.228 2.360
LS mean change from baseline (SE) 0.172 (0.092) 0.304 (0.110)
Treatment difference vs. NA 0.132
FF 100 μg (95% CI)   (-0.124, 0.388)
  1. Note: Missing data were imputed using the last observation carried forward method.
  2. CI = confidence interval; FF = fluticasone furoate; ICS = inhaled corticosteroid; LS = least squares; SE = standard error.